FGEN.O
Latest Trade
46.69USDChange
-0.95(-1.99%)Volume
494,753Today's Range
-
48.4952 Week Range
-
61.23As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 47.64 |
|---|---|
Open | 47.55 |
Volume | 494,753 |
3M AVG Volume | 16.94 |
Today's High | 48.49 |
Today's Low | 46.54 |
52 Week High | 61.23 |
52 Week Low | 32.33 |
Shares Out (MIL) | 87.21 |
Market Cap (MIL) | 4,073.71 |
Forward P/E | -209.04 |
Dividend (Yield %) | -- |
FibroCen Reports Q3 Loss Per Share $0.57
Fibrogen Says Evrenzo Approved By Japan’s Ministry of Health, Labour and Welfare
Astellas Pharma Says Japan's Ministry Of Health, Labour And Welfare Approved Evrenzo(Roxadustat)
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
Industry
Biotechnology & Drugs
Executive Leadership
James A. Schoeneck
Interim Chief Executive Officer, Director
Pat Cotroneo
Chief Financial Officer
Kin-Hung Peony Yu
Chief Medical Officer
Thomas F. Kearns
Lead Independent Director
Suzanne Blaug
Independent Director
Price To Earnings (TTM) | 113.12 |
|---|---|
Price To Sales (TTM) | 11.42 |
Price To Book (MRQ) | 6.85 |
Price To Cash Flow (TTM) | 67.43 |
Total Debt To Equity (MRQ) | 11.84 |
LT Debt To Equity (MRQ) | 9.79 |
Return on Investment (TTM) | 5.53 |
Return on Equity (TTM) | 4.81 |
China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.
* Q1 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S
* FIBROGEN INC SAYS CEO THOMAS B. NEFF'S 2017 TOTAL COMPENSATION WAS $7.1 MILLION VERSUS $5.2 MILLION IN 2016 – SEC FILING Source text (https://bit.ly/2Hpk39x) Further company coverage:
* UPDATE - FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER
* FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
* FIBROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
* Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S
* Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD)
* Announced results from co's phase 2b randomized, double-blind, placebo-controlled study in patients with idiopathic pulmonary fibrosis
* Fibrogen, Inc. announces pricing of follow-on offering of common stock
* Fibrogen Inc announces proposed follow-on offering of common stock
* Fibrogen Inc - net loss per basic and diluted share for quarter ended June 30, 2017 was $0.48 - SEC filing
* Q2 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S
* Q1 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S
* Fibrogen, Inc. announces pricing of follow-on offering of common stock
* Fibrogen announces china fda approval of cta to conduct pivotal phase 2/3 clinical trial of roxadustat in anemia associated with lower risk mds
* Fibrogen Inc files for potential mixed shelf offering; size not disclosed Source text:(http://bit.ly/2mGofE4) Further company coverage:
* Sees to report pamrevlumab topline phase 2 ipf data, placebo-controlled and combination treatment sub-study results, in q3
* FibroGen's Roxadustat (FG-4592) meets primary endpoints in two phase 3 anemia studies in China
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.